<?xml version="1.0" encoding="UTF-8"?>
<p>At least one study has evaluated the role of pro‐resolution molecules in the context of pulmonary viral infections other than influenza. Infection of 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1385" xmlns:xlink="http://www.w3.org/1999/xlink">5‐lipoxygenase (5‐LOX</ext-link>)‐deficient mice with respiratory syncytial virus (RSV) resulted in enhanced lung pathology. The 5‐LOX pathway, probably through the production of LXA4 and 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=3333" xmlns:xlink="http://www.w3.org/1999/xlink">resolvin E1</ext-link> (RvE1), appeared to be necessary for the induction of alternatively activated macrophages and induction of bronchiolitis (Shirey et al., 
 <xref rid="bph15164-bib-0035" ref-type="ref">2014</xref>). Interestingly, the specialized pro‐resolution lipid, 17‐HDHA, increased the humoral response and provided greater protective effect against live H1N1 influenza infection in mice, thus demonstrating a biological link between pro‐resolution signals and the adaptive immune system (Ramon et al., 
 <xref rid="bph15164-bib-0031" ref-type="ref">2014</xref>). Indeed, the lipoxin 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=5216" xmlns:xlink="http://www.w3.org/1999/xlink">LXB
  <sub>4</sub>
 </ext-link> was shown to boost memory B‐cell activation through 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1376" xmlns:xlink="http://www.w3.org/1999/xlink">COX‐2</ext-link> to serve as a potential vaccine adjuvant (Kim et al., 
 <xref rid="bph15164-bib-0018" ref-type="ref">2018</xref>).
</p>
